CA3127983A1 - Treatment of skin lesions and pruritus in prurigo nodularis patients - Google Patents

Treatment of skin lesions and pruritus in prurigo nodularis patients Download PDF

Info

Publication number
CA3127983A1
CA3127983A1 CA3127983A CA3127983A CA3127983A1 CA 3127983 A1 CA3127983 A1 CA 3127983A1 CA 3127983 A CA3127983 A CA 3127983A CA 3127983 A CA3127983 A CA 3127983A CA 3127983 A1 CA3127983 A1 CA 3127983A1
Authority
CA
Canada
Prior art keywords
nemolizumab
subject
pruritus
equivalent
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127983A
Other languages
English (en)
French (fr)
Inventor
Christophe Piketty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Publication of CA3127983A1 publication Critical patent/CA3127983A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3127983A 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients Pending CA3127983A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US62/797,803 2019-01-28
US201962809404P 2019-02-22 2019-02-22
US62/809,404 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Publications (1)

Publication Number Publication Date
CA3127983A1 true CA3127983A1 (en) 2020-08-06

Family

ID=69467604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127983A Pending CA3127983A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Country Status (15)

Country Link
US (2) US11236157B2 (https=)
EP (1) EP3917617A1 (https=)
JP (4) JP7410852B2 (https=)
KR (1) KR102953189B1 (https=)
CN (1) CN113660981A (https=)
AU (2) AU2020213978A1 (https=)
BR (1) BR112021014854A2 (https=)
CA (1) CA3127983A1 (https=)
CL (1) CL2021001976A1 (https=)
IL (1) IL285171B2 (https=)
MX (1) MX2021009051A (https=)
PH (1) PH12021551805A1 (https=)
SG (1) SG11202108220YA (https=)
TW (1) TWI861052B (https=)
WO (1) WO2020157636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
WO2023044313A1 (en) * 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA3199034C (en) 2015-08-24 2025-09-09 Dmk Pharmaceuticals Corporation SYRINGE-TYPE DEVICES
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Also Published As

Publication number Publication date
JP7410852B2 (ja) 2024-01-10
PH12021551805A1 (en) 2022-07-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
TW202043282A (zh) 2020-12-01
MX2021009051A (es) 2021-12-10
JP2021509103A (ja) 2021-03-18
JP2023126909A (ja) 2023-09-12
KR102953189B1 (ko) 2026-04-15
US20220177568A1 (en) 2022-06-09
JP7671822B2 (ja) 2025-05-02
CL2021001976A1 (es) 2022-02-11
US20200239563A1 (en) 2020-07-30
IL285171B1 (en) 2025-11-01
TWI861052B (zh) 2024-11-11
AU2020213978A1 (en) 2021-09-23
JP7375252B2 (ja) 2023-11-07
WO2020157636A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
CN113660981A (zh) 2021-11-16
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
IL285171B2 (en) 2026-03-01
IL285171A (en) 2021-09-30
AU2025263803A1 (en) 2025-11-27
SG11202108220YA (en) 2021-08-30
JP7309816B2 (ja) 2023-07-18
EP3917617A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
US20220177568A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
CN112689512B (zh) 用于治疗银屑病的组合物和方法
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
TW202434633A (zh) 治療甲狀腺眼疾之方法
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240124

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250121

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250121

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250704

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251031

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113